Correlation Between Genexine and INtRON Biotechnology

Can any of the company-specific risk be diversified away by investing in both Genexine and INtRON Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genexine and INtRON Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Genexine and iNtRON Biotechnology, you can compare the effects of market volatilities on Genexine and INtRON Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genexine with a short position of INtRON Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genexine and INtRON Biotechnology.

Diversification Opportunities for Genexine and INtRON Biotechnology

0.78

Correlation Coefficient

Genexine  INtRON Biotechnology

Poor diversification

The 3 months correlation between Genexine and INtRON is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Genexine and iNtRON Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on iNtRON Biotechnology and Genexine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genexine are associated (or correlated) with INtRON Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of iNtRON Biotechnology has no effect on the direction of Genexine i.e., Genexine and INtRON Biotechnology go up and down completely randomly.

Pair Corralation between Genexine and INtRON Biotechnology

Assuming the 90 days trading horizon Genexine is expected to generate 0.89 times more return on investment than INtRON Biotechnology. However, Genexine is 1.12 times less risky than INtRON Biotechnology. It trades about -0.18 of its potential returns per unit of risk. iNtRON Biotechnology is currently generating about -0.29 per unit of risk. If you would invest  534,000  in Genexine on December 30, 2024 and sell it today you would lose (124,500) from holding Genexine or give up 23.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Genexine  vs.  iNtRON Biotechnology

Genexine

Risk-Adjusted Performance

Very Weak

Over the last 90 days Genexine has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

iNtRON Biotechnology

Risk-Adjusted Performance

Very Weak

Over the last 90 days iNtRON Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Genexine and INtRON Biotechnology

The main advantage of trading using opposite Genexine and INtRON Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genexine position performs unexpectedly, INtRON Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INtRON Biotechnology will offset losses from the drop in INtRON Biotechnology's long position.

The idea behind Genexine and iNtRON Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.